Back pain: burden of comorbidities and selectic effective therapy
- Autores: Azimova Y.E.1
-
Afiliações:
- University headache clinic
- Edição: Nº 1 (2017)
- Páginas: 144-148
- Seção: Articles
- URL: https://journals.eco-vector.com/2412-4036/article/view/277692
- ID: 277692
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Back pain (dorsafgia) is the most common disease and is an actual problem of neurofogy; it most commonly leads to the development of temporary disability and limitation of activity in the working age population. Despite the fact that the earfy start of adequate therapy is crucial for the prognosis of dorsafgia, many patients seff-medicate and seek medical advice only in the case of ineffectiveness or development of side effects. Non-steroidaf anti-inffammatory drugs (NSAIDs) are drugs of choice for the refief of acute back pain, but there are fimits for use of NSAIDs, particufarfy in patients at high gastrointestinaf and cardiovascufar risk. Afternatives to NSAIDs incfude the use of sefective activators of neuronaf K-channefs. Their representative ffupirtine (Nofodatak) has anafgesic and myorefaxation effects. Some studies have shown that ffupirtine had non-inferior efficacy compared to NSAIDs, but superior safety.
Texto integral
Bibliografia
- Павленко С.С. Боли в нижней части спины (эпидемиология, клинико-диагностическая классификация, современные направления в диагностике, лечении и стандартизации медицинской помощи). Руководство. Новосибирск: Сибмедиздат НГМУ, 2007. 172 с. [Pavlenko S.S. Pain in the lower back (epidemiology, diagnostic classification, modern trends in the diagnosis, treatment and standardization of medical care). Guide. Novosibirsk: Sibmedizdat NGMA, 2007. 172 p. (in Russ.)]
- Ahuja V., Mitra S., Kazal S., Huria A. Comparison of analgesic efficacy of flupirtine maleate and ibuprofen in gynaecological ambulatory surgeries: A randomized controlled trial. Indian J. Anaesth. 2015;59(7):411-5.
- Carrasco-Garrido P., de Andrés A.L., Barrera V.H., Jiménez-Trujillo I., Fernandez-de-Las-Peñas C., Palacios-Ceña D., Garcfa-Gómez-Heras S., Jiménez-García R. Predictive factors of self-medicated analgesic use in Spanish adults: a cross-sectional national study. BMC Pharmacol. Toxicol. 2014;15:36.
- Downie A.S., Hancock M.J., Rzewuska M., Williams C.M., Lin C.W., Maher C.G. Trajectories of acute low back pain: a latent class growth analysis. Pain. 2016;157:225-34.
- Jengen M.C., Brant-Zawadzki M.N., Obuchowski N., Modic M.T., Malkasian D., Ross J.S. Magnetic resonance imaging of the lumbal spine in people without back pain. N. Engl. J. Med. 1994;331(2):69-73.
- Li C., Ni J., Wang Z., Li M., Gasparic M., Terhaag B., Uberall M.A. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr. Med. Res. Opin. 2008;24(12):3523-30.
- Machado G.C., Maher C.G., Ferreira P.H., Day R.O., Pinheiro M.B., Ferreira M.L. Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis. Ann. Rheum. Dis. 2017 Feb 2. [Epub ahead of print].
- Mishra S., Choudhary P., Joshi S., Bhatnagar S. Successful use of flupirtine in refractory neuropathic pain due to small fiber neuropathy. Am. J. Hosp. Palliat. Care. 2013;30(1):91-3.
- Moore A., Makinson G., Li C. Patient-level pooled analysis of adjudicated gastrointestinal outcomes in celecoxib clinical trials: meta-analysis of 51,000 patients enrolled in 52 randomized trials. Arthritis. Res. Ther. 2018;15(1):R6.
- Mühlbacher A.C., Junker U., Juhnke C., Stemmler E., Kohlmann T., Leverkus F., Nübling M. Chronic pain patients' treatment preferences: a discrete-choice experiment. Eur. J. Health Econ. 2015;16(6):613-28.
- Nachemson A., Jonsson E. Neck and back pain: the scientific evidence of causes, diagnosis and treatment. Philadelphia: Lippincott Williams and Wilkins, 2000.
- Rubin D.I. Epidemiology and risk factors for spine pain. Neurol. Clin. 2007;25:353-71.
- Singal R., Gupta P., Jain N., Gupta С. Role of flupirtine in the treatment of pain - chemistry and its effects. Maedica (Buchar). 2012;7(2):163-6.
- Trelle S., Reichenbach S., Wandel S., Hildebrand P., Tschannen B., Villiger P.M., Egger M., Jüni P. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:7086.
- Uberall M.A., Essner U., Müller-Schwefe G.H. 2-week efficacy and tolerability of flupirtine MR and diclofenac in patients with acute low/back pain - results of a post-hoc subgroup analysis of patient-level data from four non-interventional studies. MMW Fortschr. Med. 2013;155 (Suppl. 4-1:115-23.
- Uberall M.A., Mueller-Schwefe G.H., Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study. Curr. Med. Res. Opin. 2012;28(10):1617-34.
- Ueberall M.A., Mueller-Schwefe G.H., Terhaag B. Efficacy and tolerability of flupirtine in subacute/ chronic musculoskeletal pain - results of a patient level, pooled re-analysis of randomized, double-blind, controlled trials. Int. J. Clin. Pharmacol. Ther. 2011;49(11):637-47.
- van Tulder M., Becker A., Bekkering T., Breen A., del Real M.T., Hutchinson A., Koes B., Laerum E., Malmivaara A. European guidelines for the management of acute nonspecific low back pain in primary care. Eur. Spine J. 2006;15 (Suppl. 2):S169-91.
- Werber A., Schiltenwolf M. Treatment of lower back pain - the gap between guideline-based treatment and medical care reality. Healthcare (Basel). 2016;4(3). pii: E44
- Wolfe F., Simons D.G., Fricton J., Bennett R.M., Goldenberg D.L., Gerwin R., Hathaway D., McCain G.A., Russell I.J., Sanders H.O. The fibromyalgia and myofascial pain syndromes: a preliminary study of tender points and trigger points in persons with fibromyalgia, myofascial pain syndrome and no disease. J. Rheumatol. 1992;19(6):944-51.
Arquivos suplementares
